PierPScaglioniMD
Oncology • Cincinnati, OHHematologic Oncology
Professor Department of Internal Medicine Division of Hematology/Oncology Medical Director UC Health Barrett Cancer Center University of Cincinnati Medical College 3125 Eden Avenue, Rm. 3118 Cincinnati, OH 45219-2293
Dr. Scaglioni is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3130 Highland Ave
Cincinnati, OH 45219Phone+1 513-475-8500Fax+1 513-584-4281
Summary
- Dr. Pier Scaglioni is an oncologist in Cincinnati, OH and is affiliated with University of Cincinnati Medical Center. He received his medical degree from University of Modena Faculty of Medicine and has been in practice 28 years. He also speaks multiple languages, including Italian and Spanish. He specializes in hematologic oncology and is experienced in acute leukemias and malignant hematology.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2001 - 2004
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 1998 - 2001
University of Modena Faculty of MedicineClass of 1989
Certifications & Licensure
OH State Medical License 2017 - 2026
TX State Medical License 2007 - 2018
NY State Medical License 2001 - 2007- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 198 citationsFatty Acid Oxidation Mediated by Acyl-CoA Synthetase Long Chain 3 Is Required for Mutant KRAS Lung TumorigenesisMahesh S. Padanad, Georgia Konstantinidou, Niranjan Venkateswaran, Margherita Melegari, Smita Rindhe
Cell Reports. 2016-08-09 - 123 citationsDual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Blockade Is an Effective Radiosensitizing Strategy for the Treatment of Non–Small Cell Lung Cancer Harbori...Georgia Konstantinidou, Erik A. Bey, Andrea Rabellino, Katja Schuster, Michael S. Maira
Cancer Research. 2009-10-01 - 33 citationsPML regulates p53 stability by sequestering Mdm2 to the nucleolus.Rosa Bernardi, Pier Paolo Scaglioni, Stephan Bergmann, Henning F Horn, Karen H Vousden
Nature Cell Biology. 2004-07-01
Press Mentions
CDK4/6 Inhibitors Explored in KRAS-Mutant CancersOctober 31st, 2017
Grant Support
- Defining and Defeating Mechanistic Subtypes of KRAS-mutant Lung CancersCPRIT2016–Present
- Mutant KRAS reprograms lipid metabolism exposing beta-oxidation as a novel therapeutic target in lung cancer lung cancerCPRIT2014–Present
- Identification of critical components of the K-RAS network in lung cancerAmerican Cancer Society Scholar Award2012–2017
- Deconstruction of oncogenic K-RAS signaling reveals focal adhesion kinase as a novel therapeutic target in NSCLCDepartment of defense2012–2016
- Characterization And Drug Targeting Of The PML Tumor Suppressor In Lung CancerNational Cancer Institute2009–2011
- Post-Transcriptional Regulation Of PML FunctionNational Cancer Institute2006–2009
- Post-Transcriptional Regulation Of PML FunctionNational Cancer Institute2005–2006
Other Languages
- Italian, Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
